Professional Documents
Culture Documents
UNIT V ED F
UNIT V ED F
UNIT V ED F
ANU AGA
• MP of Rajya Sabha (Nominated)
(27 April 2012 – 26 April 2018)
• Member, National Advisory Council
(2010–2014)
• Personal detailsBorn3 August
1942 (age 76) Mumbai,India
• Nationality- Indian
• ResidencePune, India
• Alma mater- St. Xavier's College, Mumbai,
Tata Institute of Social Sciences
Occupation
• Ex-Chairperson, Thermax Ltd.,social
worker
• Anu Aga (born 1942) is an Indian billionaire businesswoman and social
worker who led Thermax, an energy and environment engineering
business, as its chairperson from 1996 to 2004.
• She had figured among the eight richest Indian women, and in 2007 was
part of 40 Richest Indians by net worth according to Forbes magazine.[
• She was awarded with the Mumbai Women of the Decade Achievers
Award by ALL Ladies League, the all ladies wing of Assocham.
• After retiring from Thermax, she took to social work, and In 2010 she was
awarded the Padma Shri for Social Work by the Government of India.
• His U.K.-educated son Adar is Serum's CEO and helps him run the
company.
• About Dr. Cyrus Poonawalla
• Dr. Poonawalla is a person who has always had a vision
of creating an atmosphere where high quality vaccines
do not remain as a mere luxury for children in India or
the world and are offered at inexpensive prices.
• Later, he decided to target the masses than the classes and hence a conversation with a vet
diverted him into vaccines.
• Poonawalla decided to take up the challenge of extracting the serum from horses himself and
producing cheaper vaccines.
• So without any delay; he along with his brother Zavaray raised $12,000 selling horses,
convinced their father to put up the rest and in 1966, Dr. Poonawalla set up the SIIL on a 12-
acre lot.
• As they had no background; they hired 10 doctors and scientists from the government-owned
Haffkine Institute of India in Mumbai. And within a span of two years Serum Institute of India
launched its first therapeutic anti-tetanus serum.
• Soon the company won contracts to supply state governments and hospitals and their sales
started getting better.
• From there onwards there was no looking back for them and the chain of events that took
place was as follows:
• In 1974, they made the DTP vaccine to protect children from diphtheria, tetanus and pertussis.
• In 1989, the production of Measles Vaccine M-Vac began and within a year SIIL became India’s
largest vaccine manufacturer.
• India became self-sufficient for Tetanus, Diphtheria and Whooping Cough vaccines; because of
SIIL.
• In 2013, Prince Charles’s keenness to know about the production of these inexpensive but high
quality vaccines forced him to make a private visit to SIIL.
BOLD POSTURE:
• Adar Poonawalla says Serum has a cash balance of about Rs 800 crore and is looking for new
They took it forward. Research was the key and by 1974, Serum introduced the DTP
1989, Serum began producing its measles vaccine, M-Vac, and within a year became the
A turning point in Serum's business came in 1994 when it got accredited by the World Health
Organization (WHO) to export vaccines from India and started supplies to UN agencies such as
Unicef and Pan American Health Organization (PAHO). Today, Serum is the world's largest
supplier of measles and DTP vaccines and controls 70 per cent of the paediatric vaccination
market in about 140 countries, except the US and the European continent.
• But that does not mean Serum is a giant in the $27-billion global vaccine market.
Novartis.
• But the ability to supply vaccines on a big scale at low prices makes Serum the most
preferred supplier of vaccines to healthcare aid agencies such as Unicef and Global
• In this space, Serum's key rivals are from India — Panacea Biotec, Bharat Biotec,
Biological E and Shanta Biotechnics (now part of Sanofi). Its overseas competitors
competition Serum institute of India does face big challenges in the near future.
• And the major reasons which could affect the company massively are its over-dependence on
public-private funded healthcare agencies. Reportedly, more than 50% of its revenues come from
the regular audits at manufacturing outlets, the UN body conducts are extremely strict and the
competent to offer vaccines at a very low price. Also because, World Health Organization has
passed China’s drug safety authority and has said that it meets the international standards for
vaccine regulation.
• Firstly, SIIL has gained a reputation in the market, so unless they screw up
badly (which is unlikely the case), any obstacle wouldn’t affect them so
much.
• And on the other hand; the over-dependency on the aforementioned
companies.
• To add to that; the Poonawalla group as a whole is expanding its genres (as